To validate MAP3K8 gene rearrangements, we performed MAP3K8 break-apart assay in all FFPE tissue samples found by RNA-Seq to carry the gene fusion. A subset of samples with alternative alterations were also included as negative controls. In addition, we performed break-apart PRKCA assay in samples found by RNA-Seq to have PRKCA gene fusion, and break-apart TERT promoter assay in both the primary biopsy and the metastatic tumor of the index case. Custom probes were generated, as previously described 41 , using bacterial artificial chromosomes (BAC) clones, obtained from BACPAC Resources of Children’s Hospital of Oakland Research Institute (Oakland, CA, USA), flanking MAP3K8 (CH17–364M4; CH17–471D1), PRKCA (CH17–384F08 and CH17–209D17), and the TERT promoter (CH17–75N21 and CH17–410B01). Break-apart FISH for ALK was performed on samples found by RNA-Seq to have ALK fusion, using commercially available probes (CytoCell, Cat# LPS 019-A). Dual-color FISH was performed on 4-μm FFPE tissue sections, as previously described 1 (link). FISH images were captured using CytoVision 7.5 software.